News

HDA UK Media And Political Bulletin – 22 March 2018

Media and Political Bulletin

22 March 2018

Media Summary

Health Select Committee warns of Brexit risks to new drugs and patient safety

Pharmaceutical Journal, 21 March 2018

 

The Pharmaceutical Journal reports that patient access to new drugs, patient safety and future investment in the life science industry are all at risk if the UK fails to maintain regulatory alignment with the European Medicines Agency (EMA).

MPs on the House of Commons Health Select Committee (HSC) also want the UK to retain membership — or at least be an observer on the EMA’s Pharmacovigilance Risk Assessment Committee — after leaving the European Union (EU), and keep its membership of EMA drugs databases.

The government, as a priority, should additionally ensure that there is “mutual recognition” of pharmacovigilance studies by EMA and the UK’s Medicines and Healthcare products Regulatory Agency, the committee said in its report ‘Brexit: medicines, medical devices and substances of human origin’.

 

BGMA reaction to the Health and Social Care Committee’s Report on Brexit: medicines, medical devices and substances of human origin

BGMA, 21 March 2018

 

The BGMA issues a statement following the publication of the Health Select Committee’s Brexit report. Warwick Smith, Director General of the British Generic Manufacturers Association, said: “The Committee’s report rightly highlights the utmost importance of maintaining the close ties with the EU after Brexit. Continued regulatory alignment, along with free and frictionless trade, will be the best way of ensuring that UK patients can continue to access a safe and secure supply of generic and biosimilar medicines.

We strongly support the Committee’s recommendations of maintaining regulatory alignment with the European Medicines Agency, and of seeking mutual recognition of standards and pharmacovigilance arrangements and Qualified Persons. Any divergence from current arrangements or additional costs of bringing medicines to market are likely to result in delays in the NHS and UK patients accessing generic medicines.”

 

Parliamentary Coverage

House of Commons – Tabled Written Question: MHRA, 21 March 2018

 

Sir David Amess: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the need for additional investment in the Medicines and Healthcare products Regulatory Agency after the UK leaves the EU.

 

Full Coverage

 Health Select Committee warns of Brexit risks to new drugs and patient safety

Pharmaceutical Journal, 21 March 2018

Patient access to new drugs, patient safety and future investment in the life science industry are all at risk if the UK fails to maintain regulatory alignment with the European Medicines Agency (EMA) after Brexit, MPs have warned.

MPs on the House of Commons Health Select Committee (HSC) also want the UK to retain membership — or at least be an observer on the EMA’s Pharmacovigilance Risk Assessment Committee — after leaving the European Union (EU), and keep its membership of EMA drugs databases.

The government, as a priority, should additionally ensure that there is “mutual recognition” of pharmacovigilance studies by EMA and the UK’s Medicines and Healthcare products Regulatory Agency, the committee said in its report ‘Brexit: medicines, medical devices and substances of human origin’.

The report said: “Failure to gain access to EU pharmacovigilance systems would have serious consequences for UK medicine and drug safety.

“It would not be possible, let alone desirable, to draw up a UK standalone system by the time the UK exits the EU. Contingency planning in this area would highlight the risks of failure to access EU pharmacovigilance systems and needs to prompt urgent action.”

The MPs went on to say: “Evidence submitted from large pharmaceutical companies, [small and medium-sized enterprises], academics, healthcare and workforce charities was all almost unanimous in the view that regulatory alignment with the EU would be the best post-Brexit option for the NHS, for patients, and for the UK life sciences industry.”

They also expressed concern about the impact of Brexit on the UK’s medicines supply chain, warning: “If the UK diverges from the EU regimes in a manner that adds to the cost and timeliness of existing supply chains, then the UK will become a less attractive market for businesses … patients in the UK would not only experience delays in access to new treatments, but could also stand to wait longer to access generic drugs coming off patent.”

The committee, made up of MPs from several parties, welcomed the government’s announcement that it had commissioned consultants Ernst & Young to carry out an analysis of the impact of Brexit on the medicines supply chain, called on ministers to publish its summary once completed, and to develop any necessary contingency plans to guarantee the safe supply of medicines after the UK leaves the EU.

The report also reiterated that it was “vital” that the UK’s life science sector continues to participate in EU-wide clinical trials after Brexit.

“If the UK does not adopt the new clinical trials regulations and is unable to access the EU infrastructure … difficulties for patients and the life science industry could emerge,” it said.

In a joint response, Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry, and Steve Bates, chief executive of the BioIndustry Association, described the HSC report as “thoughtful”.

“For medicines the detail of Brexit matters,” they said.

“To ensure uninterrupted continued supply we need rapid clarity on the legal position of medicines during the transition period from the EU and the UK. In addition, we need progress from both sides on how the desired close cooperation for the future will work in practice.”

 

BGMA reaction to the Health and Social Care Committee’s Report on Brexit: medicines, medical devices and substances of human origin

BGMA, 21 March 2018

Warwick Smith, Director General of the British Generic Manufacturers Association, said: “The Committee’s report rightly highlights the utmost importance of maintaining the close ties with the EU after Brexit. Continued regulatory alignment, along with free and frictionless trade, will be the best way of ensuring that UK patients can continue to access a safe and secure supply of generic and biosimilar medicines.

We strongly support the Committee’s recommendations of maintaining regulatory alignment with the European Medicines Agency, and of seeking mutual recognition of standards and pharmacovigilance arrangements and Qualified Persons. Any divergence from current arrangements or additional costs of bringing medicines to market are likely to result in delays in the NHS and UK patients accessing generic medicines. This is especially crucial for biosimilar medicines, as if the UK was to cease to be part of the EU regulatory framework a new route of authorisation would be need to be created to allow UK patients to benefit from these medicines. These have the potential to save hundreds of millions of pounds from the NHS medicine bill, estimated to be up to £300m a year by 2021 thus  increasing patient access to vital medicines.

“However, the Committee is right to consider the consequences of a ‘no-deal’ scenario and it is vital that the UK has sufficient contingency plans in place. The BGMA will continue to work with the Government to minimise the risk of any negative impact on patients.”

HDA UK Media And Political Bulletin – 22 March 2018

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?